The use of dietary treatments for epilepsy (ketogenic, modified Atkins, and low glycemic index diets) has been in continuous use since 1921. These treatments have been well studied in the short term, with approximately half of children having at least a 50% reduction in seizures after 6 months. Approximately one third will attain Ͼ90% reduction in their seizures. Animal studies confirm these findings, with broad evidence demonstrating acute anticonvulsant effects of the diet. Furthermore, the diet appears to maintain its efficacy in humans when provided continuously for several years. Interestingly, benefits may be seen long term even when the diet is discontinued after only a few months of use, suggesting neuroprotective effects. This potential antiepileptogenic activity has been recently demonstrated in some animal studies as well. This review discusses the animal and human evidence for both short-and long-term benefits of dietary therapies.
INTRODUCTION
Compared with most other nonpharmacologic therapies, the use of dietary therapy for epilepsy is simple, technologically. It has been in continuous use for nearly 90 years, supported by hundreds of publications describing potential benefits. 1 Although used primarily for children, diets may have a significant role in the future for adults and benefits may be identified for neurologic conditions other than epilepsy.
What are the primary dietary therapies for epilepsy? At this time, these therapies include the traditional ketogenic diet (KD), the modified Atkins diet, and the low glycemic index treatment. All three diets have been studied and are in use for both children and adults worldwide.
The KD, first introduced in 1921, 2 is high in fat, adequate for protein (1 g/kg per day), and low in carbohydrate; the diet induces high levels of serum ␤-hydroxybutyrate (and urinary acetoacetate). It is calorie and fluid restricted and traditionally is started in the hospital after a 1-to 2-day fasting period. 3 The KD can be provided as the classic diet, with predominantly long-chain triglycerides, or in a modification using gradually increasing percentages of medium-chain triglycerides.
The modified Atkins diet was introduced in 2003 and mimics the KD in composition but without calorie, protein, or fluid restriction. 4 Carbohydrates are restricted to 10 g to 15 g per day, and this diet is started on an outpatient basis without a fasting period. Similarly, the low glycemic index treatment is an outpatient-initiated therapy without restrictions on calories, protein, or fluid. 5 Unlike the modified Atkins diet, however, the low glycemic index treatment limits specific carbohydrates to those with glycemic indices of less than 50 (and those at 40 -60 g/day). Do these diets reduce seizure frequency? There is an abundance of data from both animals and humans that dietary manipulations of metabolism can positively affect seizure activity, both in the short and long term. In addition, there is evidence that diets can modify disease progression and may have neuroprotective properties. Certainly, some of the metabolic substrates elaborated by these diets have been shown in the laboratory to exert profound neuroprotective effects. Here we will discuss the evidence base for short-and long-term benefits of dietary therapies for epilepsy.
ing mechanisms of action. The earliest animal studies involving the KD focused on the acute effects of ketone bodies. In the 1930s, Keith 6 was the first to demonstrate that, in rabbits, acetoacetate (ACA) was protective against seizures induced by thujone, a convulsant constituent found in many essential oils and an antagonist of GABA A receptors. 7 This intriguing observation was confirmed in the present century by Likhodii et al., 8 who found that both ACA and acetone blocked seizure activity induced by maximal electroshock and pentylenetetrazole in rats. Acetone itself was also effective against chemically evoked atypical absence seizures. These investigators also demonstrated that acetone, when injected intraperitoneally, yielded plasma and CSF concentrations consistent with doses used to suppress seizures, supporting the unusual possibility that this volatile agent might mediate the clinical effects of the KD. Further evidence of the acute anticonvulsant effects of ACA was provided in an audiogenic seizure-susceptible mouse model that has been used in screening for investigational compounds for the treatment of epilepsy. 9 Curiously, however, although such experiments have demonstrated the acute anticonvulsant properties of ACA and acetone in vivo, there are no studies indicating that the major ketone body, ␤-hydroxybutyrate (BHB), can exert similar effects. Furthermore, in vitro experiments appear to support the notion that, unlike the medications used in clinical practice to treat epilepsy patients, BHB is not an anticonvulsant compound. Thio et al. 10 found that acute application of BHB did not affect standard measures of synaptic transmission in rat hippocampus in vitro. Over a wide concentration range (300 mol/L to 10 mmol/L), BHB did not affect GABA A receptors, ionotropic glutamate receptors, or voltagegated sodium channels. Surprisingly, despite the well known in vivo effects, ACA likewise did not affect synaptic transmission in their study. These negative findings may reflect in part the fact that 1) ketone bodies were infused acutely, not chronically; 2) experiments were conducted in normal, not epileptic, brain; and 3) both culture and perfusion media contained glucose, which might be expected to counter a ketotic environment. Taken together, the experimental evidence for whether ketone bodies exert direct anticonvulsant actions remains unclear.
Much of the existing animal literature pertaining to the KD involves rodent studies in which various high-fat treatments are implemented prior to acute provocation with either electrical stimulation or chemoconvulsant administration. Most animal diets have modeled the classic long-chain triglyceride diet originally formulated by Wilder, 2 and conform closely to either a 4:1 or approximately 6:1 ketogenic ratio of fats to carbohydrates plus protein (by weight). In general, irrespective of precise dietary formulation-as long as ketosis is seen, reflecting a shift from primarily glycolysis to intermediary metabolism-anticonvulsant effects have been observed. Thus, whether seizures are provoked by corneal electroshock, hydration electroshock, maximal electroshock, pentylenetetrazol, bicuculline, semicarbazide, kainate, flurothyl, or 6 Hz stimulation, chronic pretreatment with a KD appears to render anticonvulsant effects. [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] However, historical observations in mouse models reflecting anticonvulsant efficacy of 4:1 or 6:1 KDs may be confounded by lack of control for intake of vitamins, minerals, and antioxidants. When a balanced KD was applied in acute seizure models, anticonvulsant efficacy was not actually seen in mouse pentylenetetrazol, kainate, or flurothyl models. 23 With all of these studies, a number of experimental problems have precluded a greater understanding of the KD at a mechanistic level. Most of the problems relate to variable methodologies (e.g., use of calorie restriction, age at initiation, and duration of therapy, dietary ratios and formulations, timing of treatment, mode of seizure induction, etc.), such that cross-comparisons have been impossible to make. 24, 25 Furthermore, even in the face of prominent ketosis (i.e., Ͼ 4 mmol/L), protection against acutely induced seizure activity in animal models is not universally seen, which once again emphasizes the controversy surrounding the effects of ketone bodies.
Thavendiranathan et al. 26 examined the effects of a medium-chain triglyceride diet against electroshock-and pentylenetetrazol-induced seizures, despite the fact that ketonemia was equivalent to or substantially higher than that observed with administration of a classic long-chain triglyceride diet. Moreover, they found that the mediumchain triglyceride diet was proconvulsant in the maximal electroshock and maximal pentylenetetrazol models. 26 These studies, in attempting to mirror the clinical experience, suggest that dietary effects in controlling excitability in the brain extend beyond species boundaries, but they do little to enhance our knowledge of underlying mechanisms of action. Rather, they raise more issues and highlight the necessity of developing and studying a more clinically relevant model. One critical limitation is that these laboratory investigations have been conducted in normal, not epileptic, rodent brain. What is required is a chronic model of the KD in an animal with early-onset, medically refractory epilepsy and with a responsivity to a particular formulation of a high-fat diet that best recapitulates all of the essential elements of the human experience (Table 1) . One could reasonably argue that a direct translation of clinical protocols to the rodent may not yield similar features, but this would be at least represent a good beginning.
Human evidence
Rapidity of response. For years, anecdotal evidence has described an occasional and remarkable re-sponse to the KD within hours of its initiation. It has been reported that fasting, even before actual ketogenic food is provided, can lead to a rapid improvement in seizures. 27 More recent evidence has confirmed that the KD works quickly as an anticonvulsant. In a two-center study of 99 children who responded to the KD, the median time at which parents reported significant seizure reduction was after 5 days (range, 1-65 days). 28 Children who were fasted and improved did so more quickly, a median of 9 days more rapid (p Ͻ 0.01). 28 This rapidity of response was also seen in a double-blind, placebocontrolled, crossover design study of the KD. 29 In 20 children, the KD was provided with two fasting periods over just a 12-day period, resulting in a median reduction of 34 seizures per day, with 65% having a Ͼ50% improvement. 29 Similarly, the modified Atkins diet also appears to work very quickly. In both children and adults, improvement is seen in most patients within 14 days. 4 The data for the low glycemic index treatment in 20 children also indicate that an acute effect is present. 30 The reason why this rapid response occurs is not clear and may indicate that fasting is a distinct mechanism of action of dietary therapies.
3-to 6-month data. One of the largest prospective studies to date evaluated the outcomes of 150 consecutive children started on the KD at Johns Hopkins Hospital from 1996 to 1998. 31 At 6 months, 71% remained on the diet. Fifty-one percent had a Ͼ50% reduction in seizures, and 32% had a Ͼ90% reduction. No specific seizure type was preferentially improved, but the KD was somewhat less effective in children older than 8 years of age.
The strong evidence for short-term efficacy in multiple retrospective and prospective studies was recently summarized in a meta-analysis by Henderson et al. 1 in 2006. In this review, 50% of children had at least a 50% reduction in seizures by 6 months with 20% having a Ͼ90% reduction. Although none of the studies in the meta-analysis had a control group, the evidence was interpreted as compelling for the benefits of the KD.
Since 2006, there have been several large studies that have further demonstrated the short-term effectiveness of the KD, including some with control groups. 29, 32 In a 2008 study from London, 32 children were randomly assigned to receive the KD after either 4 weeks (treatment group) or 16 weeks (control). Of the children receiving the diet, 38% had a Ͼ50% reduction in seizures, compared to 6% of the control subjects (p Ͻ 0.0001). 32 Perhaps even more dramatic, there was a 38% decrease in the mean number of seizures with the diet, compared with an increase of 37% in the control group. A doubleblinded study of children with Lennox-Gastaut syndrome compared a treatment (saccharin solution) to a placebo (glucose solution) arm during the first 12 days of the diet after fasting periods. 29 Clinical seizures were reduced by 1.5 seizures per day with the saccharin solution, but this finding did not reach statistical significance (p ϭ 0.07). 29 When analyzing all large studies (those with more than 20 subjects) just over the past decade, the results are quite similar to those reviewed by Henderson in 2006 Reprinted with permission from Stafstrom, 1999. 25 KD ϭ ketogenic diet; MCT ϭ medium chain triglycerides; PUFA ϭ polyunsaturated fatty acids.
( Table 2) . After 6 months, 56% of 1335 patients had a Ͼ50% seizure reduction and 24% had a Ͼ90% seizure improvement.
Results from alternative diets. The modified Atkins diet and low glycemic index treatment have only recently come into clinical use, and definitive evidence of clinical effectiveness is not yet available. All studies of these diets to date have been limited to 6 months and report only short-term efficacy results. Nonetheless, the results are promising, and quite similar to the traditional KD.
The first prospective study of the modified Atkins diet in children aged 3 years to 16 years was reported in 2006. 33 Of the 20 children, 13 (65%) had a Ͼ50% seizure reduction, 7 (35%) had a Ͼ90% improvement, and 4 (20%) became seizure-free. In addition, 9/20 children were successfully able to reduce anticonvulsant medications. 33 Now, after 6 years of continuous use documented in 100 children and adults with intractable epilepsy, the numbers remain surprisingly similar: 45/100 have had at least a 50% reduction in their seizure frequency and 28/100 have Ͼ90% reduction. 4 A study from Massachusetts General Hospital in 2005 described an even less restrictive diet, the low glycemic index treatment. 30 In this study, 10 of 20 children had a Ͼ90% seizure reduction despite an absence of urinary ketones and only low levels of serum ketones. A recent review from the same center reported on 60 patients, with a 38% responder rate after 1 month.
5
Diet indications. Glucose transporter 1 (GLUT-1) deficiency syndrome and pyruvate dehydrogenase deficiency (PDHD) are now clearly indications for use of the KD, which can be life-saving. Nonetheless, given that the majority of uses of the KD have been for epilepsy, understanding which epilepsy syndromes are more likely to respond than others remains a very important question. The past decade has witnessed a strong interest in finding these ideal epileptic disorders in which the KD may show higher seizure reduction rates than the available 3-to 6-month efficacy data. These indications, which have been recently summarized in an international consensus statement on the KD, 34 include infantile spasms, tuberous sclerosis complex, myoclonic-astatic epilepsy, severe myoclonic epilepsy of infancy (Dravet syndrome), and Rett syndrome. In addition, children in certain clinical situations appear to do remarkably well: those with gastrostomy tubes, infants formula-fed only, and those with concurrent vagus nerve stimulator therapy.
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LONG-TERM BENEFITS
Animal evidence
Neuroprotection and antiepileptogenesis. In approximately 20% of patients, anticonvulsant medications can be successfully discontinued without recrudescence of seizures. It is this observation that forms the basis for the intriguing hypothesis that a KD may possess neuroprotective or antiepileptogenic properties. Although several anecdotal accounts of an enduring effect of the KD exist, recent clinical studies more strongly suggest a potential antiepileptogenic effect of the KD. 35, 36 However, it is difficult to determine whether patients who remain seizure-free after cessation of a KD have had spontaneous remission of their epilepsy or have experienced a true direct antiepileptogenic (i.e., disease-modifying) effect. Moreover, it is not possible to account for the effects of blocking seizure activity over a prolonged duration.
To date, other than anecdotal reports, there are no data from controlled studies to indicate whether the KD is in fact neuroprotective or antiepileptogenic. In considering such specific effects, it should be noted that epilepsy can develop without overt evidence of neuronal injury, 37 and neuronal damage does not necessarily lead to epilepsy. 38 Hence, the terms neuroprotection and antiepileptogenesis are not necessarily synonymous.
Despite the lack of clinical data, there are a growing number of animal and in vitro studies supporting both neuroprotective and antiepileptogenic effects of the KD. Hori et al. 39 were the first to demonstrate the long-term effects of a KD in a chronic epilepsy model. In this study, adult male rats were first subjected to electrical kindling and then, 10 days after being fully kindled, were treated with either a 4:1 KD or standard rodent chow. For 5 weeks, after-discharge threshold and duration and stage 5 seizure threshold and duration were assessed on a weekly basis. Additionally, during the 3rd week, the investigators studied the influence of a KD on learning and memory, using the standard Morris water-maze and open-field tests. The KD-fed animals exhibited an elevated afterdischarge threshold and stage 5 seizure threshold relative to controls, but this effect was transient, lasting only 2 weeks. Notably, this loss of protection occurred despite the maintenance of ketonemia. Furthermore, KD treatment did not adversely affect performance on either the water-maze or the open-field test.
This last observation contrasts with a more recent study indicating that, after lithium-pilocarpine-induced status epilepticus, KD treatment significantly impaired visuospatial learning and memory, compared with rats that were fed a regular diet. 40 Moreover, animals fed a KD exhibited significant impairment in brain growth. It remains unclear whether this was due to use of a much higher ketogenic ratio (8.6:1) than is standard practice, the long-term consequences of impaired food intake, or both. 41 Taken together, the evidence does not yet establish whether the KD preserves, enhances, or disturbs cognitive functioning in rodent models.
The first evidence that a KD can retard epileptogenesis in an animal model was demonstrated by MullerSchwarze et al. 20 In this study, rats were first subjected to kainate-induced status epilepticus, and then were treated with a KD. After the latent period, spontaneous recurrent seizures were recorded, and routine hippocampal histology and Timm histochemistry (to label zinc-containing mossy fiber terminals in the dentate gyrus) were conducted on animals after an 8-week treatment period. Seizure frequency and duration were both significantly lower in the KD-treated group than in the control group. Furthermore, although the KD did not appear to alter the degree of neuronal damage in either the CA1 or the CA3 subfields of the hippocampus, there was a substantial reduction in the extent of Timm labeling (indicative of mossy fiber sprouting).
In contrast, preliminary reports addressing the effects of a KD in the rat kainic acid model yielded somewhat contradictory results. Bough et al. 42 treated adult Sprague-Dawley rats with a KD prior to treatment with kainic acid (administered either subcutaneously or intraperitoneally). Rats fed a KD experienced more severe seizures and greater mortality than did the control animals, and this exacerbation of kainic acid-induced seizures was seen irrespective of route of administration. Similarly, in immature (P20) Sprague-Dawley rats, Ko et al. 43 found that a 2-week period of KD pretreatment exacerbated hippocampal neuronal damage in the CA1 and CA3 subfields 72 hours after kainic acid injection; no significant differences in seizure latencies were observed between the two groups.
The seemingly conflicting results of these studies may be explained in part by differences in timing of KD initiation. In the study of Muller-Schwarze et al., 20 the KD was initiated after spontaneous recurrent seizures manifested, whereas in the study by Bough et al., 42 the KD was administered prior to induction of acute seizures with kainic acid. In the case of KD treatment prior to kainic acid exposure in immature rats, 43 there may be developmental differences as well.
The conflicting results of KD treatment in rat models of status epilepticus have not been observed in studies involving mice. Noh et al. 21 examined the effects of a KD on kainate-induced hippocampal cell death in mice. Males of an outbred strain of Swiss mice (Institute for Cancer Research or ICR mice, otherwise known as Caesarean Derived-1 or CD-1) were administered kainate (25 mg/kg, intraperitoneally) after a 4-week treatment with a 4:1 KD formulation. Histological assessment of injury, using routine cresyl violet staining, in situ DNA nick-end (i.e., TUNEL) labeling, and proapoptotic caspase-3 immunoreactivity, was done at 2 days following kainate treatment. The KD-fed mice exhibited significantly prolonged seizure latency to kainate, but no changes in behavioral seizure severity were reported as compared to control animals. The kainate-treated group demonstrated typical cellular loss and pyknosis in the CA1 and CA3 hippocampal subfields, and there was marked TUNEL positivity in these regions. In contrast, KD treatment prevented cell loss and increase in DNA nick-end labeling; notably, there was a striking decrease in caspase 3 immunoreactivity in KD-fed animals. Taken together, these results indicate that pretreatment with a KD protected against kainate-induced neuronal death in mice.
In contrast to induced models, what are the effects of a KD in genetically determined epilepsy models? The seizure-susceptible EL mouse is an inbred strain that has been extensively described as a model of multifactorial idiopathic partial epilepsy with secondary generalization. 44 Generalized seizures generally manifest by the second postnatal month and persist throughout later life, but environmental stimulation such as repetitive handling can induce seizures and facilitate epileptogenesis beginning at P30. 45 Todorova et al. 46 treated male EL mice with a 4.75:1 ketogenic formula; over a 10-week period, mice were tested weekly for seizure activity induced by handling. Seizure susceptibility scores in the KD group were significantly lower than in the control mice after 3 weeks, but this difference disappeared by week 7. Overall, KD treatment delayed seizure onset in young EL mice by 1 month, and (similar to what had been reported by Hori et al. 39 in the kindling model) seizure protection was transient.
More recently, Fenoglio et al. 47 reported that a 6.3:1 KD reduced seizure frequency in Kcna1-null mice lacking the gene encoding the delayed rectifier potassium channel ␣ subunit, Kv1.1, which is important in regulating neuronal membrane excitability. This observation may be of particular interest, given that 1) Kcna1-null mice exhibit similar progressive histological changes in the hippocampus to those observed both in human epileptic tissue and in many animal models 48 of temporal lobe epilepsy and 2) the Kcna1 gene is one of only two epilepsy genes in a developmental animal model that has a homolog in a human epileptic condition. 49 
Potential Neuroprotective Mechanisms.
Ketone bodies and polyunsaturated fatty acids (PUFAs) (metabolic substrates that are both elevated in epileptic patients treated with the KD 50, 51 ) have been shown to exert neuroprotective activity in neurodegenerative conditions associated with impaired mitochondrial function. [52] [53] [54] [55] [56] [57] To date, in acute seizure or chronic epilepsy models, it is unknown whether PUFAs can exert protective effects. Willis et al. 58 administered the PUFAs eicosapentanoic acid and docosahexaenoic acid adjunctively with standard chow to normal mice, and evaluated the effects of such PUFA supplementation against acute provocation flurothyl, pentylenetetrazol, 6 Hz, and kainate models. Neither docosahexaenoic acid nor eicosapentanoic acid feeding demonstrated anticonvulsant or neuroprotective activity, despite significant alterations in the fatty acid profile in both plasma and brain. What remains unclear is whether chronic administration of PUFAs to epileptic animals would produce an altogether different effect.
Some of the salient mechanisms of neuroprotection likely involve a reduction in mitochondrial free radical production, which would decrease oxidative stress, and potentially neuronal injury. 57, [59] [60] [61] Although it remains unclear how the KD specifically produces an anticonvulsant action, the neuroprotective properties of both the KD and of ketone bodies suggest that enhanced ATP synthesis, 62, 63 increased mitochondrial uncoupling, 64 suppression of reactive oxygen species production 59, 60 , and elevated glutathione levels 61 may prevent epileptogenesis and likely as a consequence prevent recurrent seizure activity. 65 Another hypothesis for the anticonvulsant action of the KD posits that increased ATP synthesis should produce a positive bioenergetic balance, allowing stabilization of the resting membrane potential via enhanced activity of Naϩ, Kϩ, and ATPase. 66 Several decades ago, DeVivo et al. 63 reported that the KD increased the total quantity of bioenergetic substrates (such as ATP and phosphocreatine) and elevated the energy charge in rat brain. These changes were thought to stabilize the cell membrane, especially in the face of excessive excitation and energy demand. Consistent with these observations, a subsequent human study using magnetic resonance spectroscopic techniques indicated that patients with epilepsy fed a KD had elevated levels of both phosphocreatine and creatine in the brain. 67 Recent animal studies have further supported the bioenergetic theory of KD action. Using cDNA microarray technology, increased expression of the mitochondrial ATP synthase ␤, subunit D, was reported after KD treatment in mice. 68 In the most comprehensive study of this kind to date, the KD was found to enhance mitochondrial biogenesis and significantly increase the number of transcripts encoding energy metabolism genes in rats. 62 This increase in bioenergetic capacity enabled hippocampal slices from these animals to better withstand metabolic challenge from low glucose exposure. Taken together, the prevailing notion is that increased energy production and reserve capacity enable greater resistance to neuronal hyperexcitability and injury.
Other mechanistic considerations. Glucose restriction has long been implicated in the mechanisms of KD action, 57, 66, 69 based on the clinical observation of mild glucopenia in treated epilepsy patients. Thus, it is of considerable interest that Garriga-Canut et al. 70 demonstrated that 2-deoxyglucose (2-DG) (an inhibitor of phosphoglucose isomerase) potently inhibited seizure progression in the rat kindling model of temporal lobe epilepsy, and decreased the expression of brain-derived neurotrophic factor BDNF and its principal receptor, TrkB. These effects were linked to the induction of the transcription factor NRSF (neuron restrictive silencing factor), a master negative regulator of neuronal genes. In preclinical screening models, Stafstrom et al. 71 evaluated the effects of 2-DG in multiple in vitro and in vivo models and found that 2-DG exerted acute anticonvulsant and chronic antiepileptic actions with a novel pattern of effectiveness.
In a related direction, Lian et al. 72 demonstrated that fructose-1,6-bisphosphate, a metabolite that shifts the metabolism of glucose from glycolysis to the pentose phosphate pathway, exhibits potent anticonvulsant activity in several rat models of acute seizures (i.e., pilocarpine, kainic acid, and pentylenetetrazole); efficacy in these models exceeded that of 2-DG and KD treatment.
Collectively, emerging data indicate that the overall strategy of limiting glycolytic flux may be a powerful way of preventing acute seizures and perhaps epileptogenesis as well. It remains to be established whether glucose restriction allows for a compensatory increase in fatty acid oxidation leading to elevated ketone body production, or to enhanced flux of tricarboxylic acid intermediates (e.g., by administering anaplerotic substrates that can replenish a depleted tricarboxylic acid pool; K. Borges, personal communication). Taken together, the evidence to date strongly suggests that metabolic regulation is a potential therapeutic strategy for seizure suppression and modulation of epileptogenesis.
Human evidence
KD for 3 to 6 years. A common misconception is that the KD not only must be discontinued after 2 years due to side effects, but also that efficacy will wane over time. This does not appear to be true, based on recent studies that examined the long-term efficacy of the KD after periods longer than 6 to 12 months. In the largest long-term study to date, children from the original 150 patient cohort first reported in 1998 31 were contacted again after 3 to 6 years. 35 Using an intent-to-treat analysis, 65 (43%) had a Ͼ50% seizure reduction when followed, including many who were now off the KD. 35 For those who remained on the diet for more than 4 years, 13 of 15 (87%) had Ͼ50% reduction in seizures.
These benefits were noted not only in those who remained on the KD for extended periods of time. Of these original 150 children, 28 discontinued the KD before 6 months of use (most because of KD inefficacy) and were then analyzed separately. 36 Although one would expect them to be doing poorly 3 to 6 years later, in fact 12 of the 28 children (43%) were Ͼ50% improved, which was similar to the overall population. 36 Five of these children had surgery to improve their epilepsy, but (surprisingly) seven did not.
KD for 6 to 12 years. The KD appears to be effective even beyond 6 years. At Johns Hopkins Hospital, of approximately 600 children who have been started on the diet since 1994, 28 children had been continuously on the KD for more than 6 years (range, 6 -12 years) when analyzed in 2006. 73 The majority of these children remained on the KD because of dramatic seizure reduction and then, because this did not reach the level of seizure freedom, the KD was maintained. Even after these extended periods, all children maintained large urinary ketosis and control was stable, with only periodic breakthrough seizures. Of these 28 children, 24 (86%) were reported as having Ͼ90% seizure reduction. This patient's family had continuously provided the KD for nearly a decade without neurologist or dietitian supervision. To date, he remains on a 3:1 KD with large ketosis and Ͼ90% seizure reduction, with approximately 1-2 seizures per year. His parents provide his KD, which he brings daily to work, and he does not appear to have tolerability issues.
Results from this study and the others discussed in this review suggest that the benefits of the KD can be seen long term and do not diminish over time. They may even persist for years after the KD is stopped. For patients in whom the KD proves useful and necessary long-term, it may be reasonable (given the potential side effects of the KD from extended use, including kidney stones, bone fractures, and decreased linear growth 73 ) to consider changing to the modified Atkins treatment or low glycemic index treatment after several years. For now, however, because these alternative diets have only recently been introduced, we do not yet know the long-term efficacy profile, nor whether they truly have fewer longterm side effects than the KD.
CONCLUSION
In summary, the traditional and alternative KDs appear to show significant immediate and short-term benefits. This effect is seen in both animal and human studies. Because it has been in use for nearly a century, the KD has also had sufficient time to demonstrate long-term clinical benefits in those who maintain it and-notablyeven in those who discontinue it. Recent animal studies have also confirmed this finding that the KD and its metabolic substrates may exert neuroprotective properties. Further studies of dietary therapies are necessary and ongoing.
